RxDoctor Payments Data

Theresa Hall, APRN

Gerontology · Wasilla, AKNPI 1265984181

Payments from drug & device makers

$2,523in general payments, 2019–2025

Across 75 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$791
  • Novartis$715
  • Amgen$194
  • Abbott$192
  • Inari Medical, Inc.$133
  • Sanofi-aventis U.S. LLC$126
  • plus $372 from 8 others

What the payments were for

  • Food & beverage$2,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gerontology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$48,953
Medicare patients
327
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$55,702
EntrestoSacubitril/Valsartan28$41,826
XareltoRivaroxaban20$31,048
JardianceEmpagliflozin13$19,896
BrilintaTicagrelor13$15,635
Atorvastatin Calcium78$1,650
Ezetimibe30$1,602
Rosuvastatin Calcium41$1,525
Metoprolol Succinate92$1,523
ClopidogrelClopidogrel Bisulfate70$1,386
Carvedilol81$922
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$609
Lisinopril56$568
Potassium Chloride12$475
Losartan Potassium38$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$55,70243 claims
NovartisEntresto$715$41,82628 claims
Johnson & JohnsonXarelto$12$31,04820 claims
Boehringer IngelheimJardiance$18$19,89613 claims
AstraZenecaBrilinta$88$15,63513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other gerontology in Wasilla

Where these figures come from

Is this you, or does something look wrong? →